Traduction de «demande d'achat commandée partiellement » (Français → Anglais) :

Appeal brought against the judgment of the General Court (Third Chamber) of 5 October 2011 in Case T-39/06 Transcatab v Commission, in which the General Court dismissed the application for the partial annulment of Commission Decision C(2005) 4012 final of 20 October 2005 relating to a proceeding under Article 81(1) [EC] (Case COMP/C.38.281/B.2 — Raw tobacco — Italy) and for a reduction of the fine imposed on Transcatab by that decision and the counterclaim by the Commission seeking to increase that fine — Italian market for the purchasing and primary processing of raw tobacco — Attribution of liability to a parent company for infringemen ...[+++]ts of competition rules committed by its subsidiaries — Rebuttable presumption in the case of a 100 % shareholding — Fundamental principles governing the taking of evidence — Obligation to state the reasons on which a decision is based — Rights of the defence — Principle of equal treatment

With regard to the purchase of mefloquine from the manufacturer and the oversight of mefloquine by the Health Protection Branch as mandated by the Food and Drug Act: (a) did the Canadian Forces indicate to the manufacturer on the order form when ordering mefloquine for Somalia that it was for use under the Food and Drug Act's Lariam Safety Monitoring Study; when was the order submitted; and when was the shipment received; (b) was the Health Protection Branch informed by the manufacturer that the Canadian Forces had indicated on the order form that the mefloquine was being ordered under the authority of the Lariam Safety Monitoring Stu ...[+++]dy and that this mefloquine was apparently purchased for the Somalia deployment; and when was the Health Protection Branch so informed; (c) did the Health Protection Branch receive from the manufacturer a request to fast track licensing approval for mefloquine (Lariam), and was licensing approval granted prior to the end of the Canadian Forces deployment in Somalia; (d) what was the date the Health Protection Branch received the final results of the Lariam Safety Monitoring Study from the manufacturer, and the date of the receipt by the Health Protection Branch of the last submission of the Safety Monitoring Study's results prior to licensing approval; (e) did the Department of National Defence prepare an advisory note acknowledging that evidence provided to the Somalia Inquiry had mislead the Inquiry as to the status of mefloquine approvals for the mefloquine used in the Somalia deployment; was the advisory note forwarded to the Minister of National Defence; and what action was taken when the Minister was so informed?

55. Calls for collaboration with the pharmaceutical industry on poverty diseases, with a new framework proposal for RD in such diseases, to provide incentives for investment, including protocol assistance, fee waivers, tax credits, subsidies, innovation prizes, assistance for prequalification, advance purchase commitments and partial transfer of patent rights to drugs; and calls also for a "needs based approach";

55. Calls for collaboration with the pharmaceutical industry on poverty diseases, with a new framework proposal for RD in such diseases, to provide incentives for investment, including protocol assistance, fee waivers, tax credits, subsidies, innovation prizes, assistance for prequalification, advance purchase commitments and partial transfer of patent rights to drugs; and calls also for a "needs based approach";